Yan Li

发表

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects

S. Zhou, M. Palmisano, K. Ogasawara, 2019, Journal of clinical pharmacology.

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration

M. Carleton, W. Kerwin, R. Chopra, 2015, Cancer Chemotherapy and Pharmacology.

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects

S. Zhou, M. Palmisano, Chengyue Zhang, 2018, Journal of clinical pharmacology.

Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.

S. Zhou, M. Palmisano, Yan Li, 2015, Molecular pharmaceutics.

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

R. Chopra, S. Zhou, M. Palmisano, 2014, Journal of clinical pharmacology.

Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.

Hebao Yuan, S. Zhou, M. Palmisano, 2018, Molecular pharmaceutics.

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

S. Zhou, M. Palmisano, Jian Chen, 2019, Oncology and Therapy.

Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients

S. Zhou, Yan Li, N. Chen, 2022, EJHaem.

Population Pharmacokinetics and Exposure‐Response Analysis of nab‐Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors

S. Zhou, M. Palmisano, Yan Li, 2020, Clinical pharmacology in drug development.

Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

Hebao Yuan, Wei Gao, Hongxiang Hu, 2021, Biomaterials.

Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia

K. Takeshita, S. Zhou, M. Palmisano, 2017, Journal of clinical pharmacology.

Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.

Hebao Yuan, S. Zhou, M. Palmisano, 2017, International journal of pharmaceutics.

Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.

Hebao Yuan, S. Zhou, M. Palmisano, 2019, Molecular pharmaceutics.

Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans

Hebao Yuan, S. Zhou, Duxin Sun, 2018, Clinical pharmacology : advances and applications.

Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide R- and S-Enantiomers

S. Zhou, M. Palmisano, Yan Li, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide Rand S-Enantiomers

S. Zhou, M. Palmisano, Yan Li, 2014 .

Population Pharmacokinetics of Pomalidomide

Yejun Xu, S. Zhou, M. Palmisano, 2015, Journal of clinical pharmacology.

A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension

S. Zhou, M. Palmisano, Liangang Liu, 2018, Clinical pharmacology : advances and applications.

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

S. Zhou, M. Palmisano, K. Ogasawara, 2019, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects

S. Zhou, M. Palmisano, Liangang Liu, 2018, Pharmacology research & perspectives.

Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans

S. Surapaneni, Yan Li, Xiaomin Wang, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase

S. Zhou, Liangang Liu, Yan Li, 2022, Journal of clinical pharmacy and therapeutics.

Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

S. Zhou, Leon Carayannopoulos, Yan Li, 2021, Journal of clinical pharmacology.

Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety

Hebao Yuan, Hongxiang Hu, S. Zhou, 2022, Acta pharmaceutica Sinica. B.

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton’s Tyrosine Kinase Inhibitor

S. Zhou, Liangang Liu, Yan Li, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics

S. Zhou, M. Palmisano, Liangang Liu, 2018, Clinical pharmacology in drug development.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

M. Dimopoulos, P. Sonneveld, K. Ramasamy, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

M. Dimopoulos, P. Sonneveld, D. Siegel, 2017, Clinical pharmacology : advances and applications.

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

C. Hofmeister, S. Lonial, J. Laubach, 2015 .

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

Hua Yang, S. Surapaneni, Yan Li, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

S. Zhou, M. Palmisano, Yan Li, 2019, Clinical pharmacology : advances and applications.

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone

S. Zhou, M. Palmisano, Yan Li, 2020, Journal of clinical pharmacology.

Slow drug delivery decreased total body clearance and altered bioavailability of immediate‐ and controlled‐release oxycodone formulations

S. Zhou, M. Palmisano, Duxin Sun, 2016, Pharmacology research & perspectives.

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects

Mahmoud S. Assaf, M. Palmisano, Liangang Liu, 2015, Journal of clinical pharmacology.

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies

S. Zhou, M. Palmisano, Duxin Sun, 2020, Clinical pharmacology : advances and applications.

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Ef ﬁ cacy and Safety Pro ﬁ les in Clinical Studies Pharmacology: and Applications

S. Zhou, M. Palmisano, Duxin Sun, 2020 .

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

C. Hofmeister, S. Lonial, J. Laubach, 2013 .

Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma

P. Maciag, S. Zhou, Yan Li, 2022, British journal of clinical pharmacology.

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

Atalanta Ghosh, S. Zhou, Yan Li, 2023, Clinical pharmacology : advances and applications.

Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide

S. Zhou, Liangang Liu, Yan Li, 2023, Clinical pharmacology in drug development.

Population Pharmacokinetics of CC-122

S. Zhou, M. Pourdehnad, Jian Chen, 2021, Clinical pharmacology : advances and applications.

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

S. Lonial, D. Siegel, R. Harvey, 2013 .

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

M. Czuczman, V. Komashko, S. Zhou, 2019, Clinical Pharmacokinetics.

Single‐Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC‐122) in Subjects With Mild, Moderate, or Severe Renal Impairment

S. Zhou, M. Palmisano, Kimberly MacGorman, 2019, Clinical pharmacology in drug development.

Exposure-response analysis to assess the concentration–QTc relationship of CC-122

S. Zhou, M. Palmisano, Leon Carayannopoulos, 2016, Clinical pharmacology : advances and applications.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

C. Hofmeister, S. Lonial, D. Siegel, 2017, Leukemia.